Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (5339)	1/13/1998 10:47:00 AM
From: aknahow	Respond to of 17367

Bob, I could find nothing on the URL for the Foundation that indicated any awareness of the existance of trials for Neuprex. Knowing of an outbreak in a school at least gets parents to pay more attention to mundane flu like symptoms and also should alert the doctors in the area to consider the worst. BTW nice article on ICOS in todays IBD. Graph on patent apps filed since 1990. Has had 135 aps with 25 issued. Has 12 drugs in development 5 in trials of which P III to begin shortly for one. Think about XOMA, it would appear to have ICOS beat except in market performance. Would like to see similar patent/trials article on Xoma.